Study Overview: This study looks at the safety of a drug called Resmetirom, or MGL-3196, for people with Non-alcoholic Fatty Liver Disease (NAFLD). NAFLD is when fat builds up in your liver without drinking too much alcohol. This study lasts for 52 weeks (about a year) and is open-label, meaning everyone knows they are getting the drug. Participants will take the medicine once a day by mouth.

Eligibility: To join, you must have already been in a similar study or meet specific health criteria, including certain liver test results. If you've had too much alcohol recently, other liver problems, or certain kinds of cancer, you can't join.

• The study lasts 52 weeks and involves taking a daily pill.
• You must have completed a previous study or meet certain liver health criteria to participate.
• People with certain health conditions, like heavy alcohol use or cancer, cannot participate.